Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

686
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
686
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.7K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.7K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

682
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
682
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

629
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
629
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

712
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
712
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

836
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
836

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systematic Evaluation of Data and Trial Fitness for Oncology Trial Emulation: Empirical Findings from the CARE Initiative.

Clinical pharmacology and therapeutics·2026
Same author

Inhaler recognition as a marker for adherence in pediatric patients with asthma.

Allergy and asthma proceedings·2026
Same author

Predictors for T cell receptor excision circles in infants without severe combined immunodeficiency or thymic aplasia/hypoplasia.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir-rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study.

The lancet. HIV·2026
Same author

Intraoperative Discovery of Bioprosthetic Mitral Valve Thrombus on TEE During HeartMate 3 Implantation: Implications for Anesthetic Management and Surgical Planning.

Seminars in cardiothoracic and vascular anesthesia·2026
Same author

Topical Capsaicin for Symptomatic Treatment of Cannabinoid Hyperemesis Syndrome in a Pregnant Patient: A Case Report.

Pain medicine case reports·2025

Related Experiment Video

Updated: Oct 18, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K

New Treatments for Asthma.

Jenny Huang1, Milind Pansare2

  • 1Division of Allergy and Immunology, Department of Pediatrics,Children's Hospital of Michigan, Suite #4022, 4th Floor, 3950 Beaubien Boulevard, Detroit, MI 48201, USA.

Immunology and Allergy Clinics of North America
|October 4, 2021
PubMed
Summary

New biologic therapies effectively treat T2 high asthma, but T2 low asthma management remains difficult. Current asthma guidelines require updates to include these advanced therapeutic options for better patient outcomes.

Keywords:
Asthma endotypesBiologicsBronchial thermoplastyLong-acting antimuscarinic agentsSevere asthma

More Related Videos

Acupuncture in a Rat Model of Asthma
07:14

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

6.2K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.9K

Related Experiment Videos

Last Updated: Oct 18, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K
Acupuncture in a Rat Model of Asthma
07:14

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

6.2K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.9K

Area of Science:

  • Pulmonology
  • Immunology
  • Pharmacology

Background:

  • Asthma is a prevalent, complex chronic airway disease characterized by significant rates of uncontrolled cases.
  • Existing treatments inadequately address the heterogeneity of asthma, particularly in specific patient subgroups.
  • Recent advancements have introduced novel therapeutic agents, including biologics, targeting distinct asthma phenotypes.

Purpose of the Study:

  • To review the current therapeutic landscape for asthma, focusing on T2-high and T2-low phenotypes.
  • To highlight the efficacy of new biologic therapies in managing T2-high asthma.
  • To identify the unmet needs in T2-low asthma treatment and inform guideline updates.

Main Methods:

  • Literature review of recent clinical trials and treatment guidelines for asthma.
  • Analysis of treatment outcomes for biologics in T2-high asthma patients.
  • Assessment of challenges and potential strategies for T2-low asthma management.

Main Results:

  • Biologic therapies have shown significant efficacy in controlling T2-high asthma.
  • Effective treatment options for T2-low asthma remain limited, presenting a clinical challenge.
  • Current asthma management guidelines do not fully incorporate the latest therapeutic advancements.

Conclusions:

  • While T2-high asthma benefits from new biologics, T2-low asthma requires further research and therapeutic development.
  • Updates to clinical asthma guidelines are crucial to integrate novel treatments and improve patient care.
  • Personalized medicine approaches are needed to address the heterogeneity of chronic airway diseases like asthma.